STLN
Starling Oncology Inc.
STLN | NASDAQ
$6.38
-$0.15 (-2.30%)
Nov 2, 2026, 12:14 PM ET · Market open
Company Profile
Starling Oncology, Inc., formerly The Oncology Institute, is a value-based oncology company advancing cancer care in the community setting. Founded in 2007, the company offers cutting-edge, evidence-based cancer treatments, including clinical trials and transfusions, to a large patient population. It operates as an integrated oncology platform serving patients, providers, and health plans across multiple markets with a focus on delivering high-quality, patient-centered care.
Key Executives
| Name | Position |
|---|---|
| Daniel Virnich FACHE | CEO & Executive Director |
| Minh Merchant | Chief Legal Officer |
| Nolan Mariano | Chief People Officer |
| Rakesh Panda | Chief Information Officer |
| Robert Carter | Chief Financial Officer |
| Austin Lee | VP of Accounting & Controller |
| Jordan McInerney | Chief Development Officer |
| Mark Hueppelsheuser | General Counsel |
| Stephen Cella | Senior Vice President of Finance |
| Yale D. Podnos | Chief Medical Officer |
Starling Oncology Inc.
STLN
| Country | United States |
| IPO Date | Aug 4, 2026 |
| Industry | Medical - Care Facilities |
| Sector | Healthcare |
| Employees | 641 |
| CEO | Daniel Virnich |
Contact Details
18000 Studebaker Road, Suite 800 Cerritos,
California 90703 United States
Stock Details
| Ticker Symbol | STLN |
| Exchange | NASDAQ |
| Fiscal Year | n/a |
| Reporting Currency | USD |
| CIK Code | 0001799191 |
| CUSIP Number | 68236X100 |
| ISIN Number | US68236X1000 |
| SIC Code | n/a |
Add to Watchlist
Select watchlists to add or remove STLN